Exelixis Inc. buy klostergang
Start price
29.01.18
/
50%
€27.35
Target price
29.01.19
€35.18
Performance (%)
-23.88%
End price
29.01.19
€20.82
Summary
This prediction ended on 29.01.19 with a price of €20.82. The prediction for Exelixis Inc. disappointed with a performance of -23.88%. klostergang has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Exelixis Inc. | 3.064% | 3.064% | 19.678% | 53.951% |
| iShares Core DAX® | 1.280% | 1.320% | 13.605% | 15.782% |
| iShares Nasdaq 100 | -2.457% | -5.192% | 25.941% | 38.434% |
| iShares Nikkei 225® | -2.006% | -1.389% | 8.973% | 6.570% |
| iShares S&P 500 | -0.662% | -1.884% | 23.684% | 39.611% |
Comments by klostergang for this prediction
In the thread Exelixis Inc. diskutieren
klostergang stimmt der Buy-Einschätzung von stratec zu
klostergang stimmt am 29.01.2018 der Buy-Einschätzung von stratec mit dem Kursziel 34$ zu.
Überschrift: EXEL is currently becoming a key player in the kidney cancer space
Update:
The stock sold off after fourth-quarter earnings, but the long-term thesis appears intact as label expansion for cabozantinib and other bullish drivers should kick in in the medium term. Near-term weakness, long-term outperformance is my initial impression.
(Laufzeit überschritten)